Nothing Special   »   [go: up one dir, main page]

CO5261589A1 - Compuestos heterociclicos, su produccion y su utilizacion - Google Patents

Compuestos heterociclicos, su produccion y su utilizacion

Info

Publication number
CO5261589A1
CO5261589A1 CO01027571A CO01027571A CO5261589A1 CO 5261589 A1 CO5261589 A1 CO 5261589A1 CO 01027571 A CO01027571 A CO 01027571A CO 01027571 A CO01027571 A CO 01027571A CO 5261589 A1 CO5261589 A1 CO 5261589A1
Authority
CO
Colombia
Prior art keywords
production
jpeg
formula
alkyl group
represented
Prior art date
Application number
CO01027571A
Other languages
English (en)
Inventor
Akihiro Tasaka
Hitaka Takenori
Matsutani Etsuya
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of CO5261589A1 publication Critical patent/CO5261589A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto caracterizado por que está representado por la fórmula:<EMI FILE="01027571_1" ID="1" IMF=JPEG >en donde n es de valor 1 ó 2;R1 es un átomo halógeno o un grupo alquilo C1-2 opcionalmente halogenado;uno de R2 y R3 es un átomo de hidrógeno y el otro es un grupo representado por la fórmula:<EMI FILE="01027571_2" ID="2" IMF=JPEG >en donde n es 3 ó 4; R4 es un grupo alquilo C1-4 sustituido por 1 o 2 grupos hidroxilo, o una sal del mismo.
CO01027571A 2000-04-07 2001-04-06 Compuestos heterociclicos, su produccion y su utilizacion CO5261589A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000106836 2000-04-07

Publications (1)

Publication Number Publication Date
CO5261589A1 true CO5261589A1 (es) 2003-03-31

Family

ID=18619943

Family Applications (1)

Application Number Title Priority Date Filing Date
CO01027571A CO5261589A1 (es) 2000-04-07 2001-04-06 Compuestos heterociclicos, su produccion y su utilizacion

Country Status (19)

Country Link
US (2) US6716863B2 (es)
EP (1) EP1268473A1 (es)
KR (1) KR20020028865A (es)
CN (1) CN1444582A (es)
AU (1) AU2001244726A1 (es)
BR (1) BR0109851A (es)
CA (1) CA2404760A1 (es)
CO (1) CO5261589A1 (es)
CZ (1) CZ20023264A3 (es)
EE (1) EE200200576A (es)
HU (1) HUP0300434A3 (es)
IL (1) IL152115A0 (es)
MX (1) MXPA02009621A (es)
NO (1) NO20024742L (es)
OA (1) OA12244A (es)
PE (1) PE20011178A1 (es)
PL (1) PL365787A1 (es)
SK (1) SK14132002A3 (es)
WO (1) WO2001077107A1 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1322139A (zh) * 1998-10-08 2001-11-14 武田药品工业株式会社 阻滞激素依赖性癌症向激素非依赖性癌症转化的药物
CA2415961A1 (en) * 2000-07-19 2002-01-24 Hirohiko Nishiyama Production method of 1-substituted-1,2,3-triazole derivatives
CA2444727A1 (en) * 2001-04-25 2002-11-07 Takeda Chemical Industries, Ltd. Agents for preventing postoperative recurrence of premenopausal breast cancer
US20040138160A1 (en) * 2001-04-27 2004-07-15 Kenichiro Naito Preventive/therapeutic method for cancer
WO2002087618A1 (fr) * 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Methode de prevention et de traitement du cancer
CA2458452C (en) * 2001-08-10 2011-04-19 Takeda Chemical Industries, Ltd. Gnrh agonist combination drugs
US6984653B2 (en) * 2001-10-05 2006-01-10 Takeda Pharmaceutical Company Limited Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof
CA2466659A1 (en) 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Anticancer agents
US7622479B2 (en) * 2001-11-26 2009-11-24 Takeda Pharmaceutical Company Limited Bicyclic derivative, its production and use
WO2003059907A1 (fr) * 2002-01-17 2003-07-24 Takeda Chemical Industries, Ltd. Composes heterocycliques azotes : procede de preparation et d'utilisation
EP1572083A4 (en) 2002-04-25 2008-09-24 Univ Connecticut Health Ct USE OF THERMAL SHOCK PROTEINS TO IMPROVE THE THERAPEUTIC ADVANTAGE OF NON-VACCINAL TREATMENT MODALITY
CA2507002C (en) * 2002-12-16 2012-09-18 Kissei Pharmaceutical Co., Ltd. Solid drug for oral use
TW200505913A (en) * 2003-03-28 2005-02-16 Hoffmann La Roche Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
TW200423931A (en) * 2003-04-30 2004-11-16 Hoffmann La Roche Novel aniline derivatives, their manufacture and use as pharmaceutical agents
US7247649B2 (en) 2003-08-13 2007-07-24 Hoffmann-La Roche Inc. Oxazoles, their manufacture and use as pharmaceutical agents
US7259262B2 (en) 2003-10-24 2007-08-21 Hoffmann-La Roche Inc. Arylazole derivatives, their manufacture and use as pharmaceutical agents
US20050186275A1 (en) * 2004-02-23 2005-08-25 Standard Chem. & Pharm. Co. Ltd. Sustained release tamsulosin formulations
TW200612914A (en) 2004-03-05 2006-05-01 Hoffmann La Roche Novel oxidized thioether derivatives, their manufacture and use as pharmaceutical agents
TW200531688A (en) 2004-03-05 2005-10-01 Hoffmann La Roche Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
TW200533346A (en) * 2004-03-18 2005-10-16 Hoffmann La Roche Novel ether derivatives, their manufacture and use as pharmaceutical agents
WO2005097785A1 (en) * 2004-04-02 2005-10-20 F.Hoffmann-La Roche Ag Novel diazine derivatives, their manufacture and use as pharmaceutical agents
US7005526B2 (en) * 2004-05-25 2006-02-28 Hoffmann-La Roche Inc. Thioether derivatives
US7163953B2 (en) * 2004-05-25 2007-01-16 Hoffmann-La Roche Inc. Benzylether derivatives
US7618769B2 (en) * 2004-06-07 2009-11-17 Applied Materials, Inc. Textured chamber surface
US7288557B2 (en) 2004-09-21 2007-10-30 Hoffmann-La Roche Inc. Triazole derivatives
US7342030B2 (en) 2004-09-22 2008-03-11 Hoffmann-La Roche Inc. Indole derivatives
AR050652A1 (es) * 2004-09-24 2006-11-08 Hoffmann La Roche Derivados de oxazol, preparacion y uso como inhibidores de la tirosina quinasa
US20060116407A1 (en) * 2004-11-22 2006-06-01 Birgit Bossenmaier Amide derivatives
TW200727900A (en) * 2005-07-27 2007-08-01 Yakult Honsha Kk Aqueous solution preparation containing camptothecins
TW200738680A (en) * 2005-08-04 2007-10-16 Hoffmann La Roche Phenylpyridine derivatives, their manufacture and use as pharmaceutical agents
US20090264485A1 (en) * 2005-08-08 2009-10-22 Hans-Willi Krell Pyrazole Derivatives, Their Manufacture and Their Use as Pharmaceutical Agents
WO2007039226A1 (en) * 2005-09-30 2007-04-12 F. Hoffmann-La Roche Ag Diazine azole derivatives, their manufacture and use as pharmaceutical agents
WO2008034579A1 (en) * 2006-09-20 2008-03-27 F. Hoffmann-La Roche Ag 2-heterocyclyl-5-phenoxymethylpyridine derivatives as anticancer agents
JPWO2008072634A1 (ja) 2006-12-12 2010-04-02 武田薬品工業株式会社 縮合複素環化合物
EP2140883B1 (en) 2007-04-20 2012-10-31 Daido Chemical Corporation Novel base for dry solid dispersion, solid dispersion containing the base, and composition containing the dispersion
PE20091580A1 (es) 2008-03-12 2009-11-05 Takeda Pharmaceutical Compuesto heterociclico fusionado
WO2010036917A1 (en) * 2008-09-26 2010-04-01 Takeda Pharmaceutical Company Limited Prevention and treatment of cancer with ras gene mutation
TW201016703A (en) * 2008-09-26 2010-05-01 Takeda Pharmaceutical Prevention and treatment of cancer with LKB1 non-expression (deletion or mutation)
WO2011039952A1 (ja) 2009-09-30 2011-04-07 株式会社サンギ 難溶性物質の水溶解性改善方法
EP2540286A4 (en) 2010-02-26 2015-05-27 Nisshin Kasei Co Ltd HARD CAPSULE AND METHOD OF PRODUCING THE SAME
US9265739B2 (en) 2010-06-02 2016-02-23 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to HER2/neu receptor complex
WO2011153049A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
JP5909796B2 (ja) 2012-03-02 2016-04-27 株式会社サンギ 難溶性物質の水溶解性改善方法
JP6225113B2 (ja) 2012-09-26 2017-11-01 武田薬品工業株式会社 固体粒子の製造方法
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
CN107922609B (zh) 2015-07-01 2020-04-24 加州理工学院 基于阳离子粘酸聚合物的递送系统
EP3238711B1 (en) 2016-04-26 2023-07-12 Mitsubishi Chemical Corporation Base for solid dispersion, production method for solid dispersion using same, and solid dispersion
CA2995617A1 (en) * 2017-11-03 2019-05-03 Universite De Montreal Heterocyclic mitochondrial activity inhibitors and uses thereof
US20190381188A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same
TW202038957A (zh) 2018-12-21 2020-11-01 日商第一三共股份有限公司 抗體-藥物結合物與激酶抑制劑之組合
WO2021118924A2 (en) 2019-12-12 2021-06-17 Ting Therapeutics Llc Compositions and methods for the prevention and treatment of hearing loss
CN114217025B (zh) * 2021-12-17 2024-01-23 哈尔滨工业大学 评估空气质量浓度预测中气象数据对其影响的分析方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0525109A4 (en) 1990-04-16 1993-06-30 Rhone-Poulenc Rorer International (Holdings) Inc. Styryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit egf receptor tyrosine kinase
AU3461697A (en) * 1996-07-19 1998-02-10 Takeda Chemical Industries Ltd. Heterocyclic compounds, their production and use

Also Published As

Publication number Publication date
CZ20023264A3 (cs) 2003-02-12
WO2001077107A1 (en) 2001-10-18
BR0109851A (pt) 2003-06-03
OA12244A (en) 2006-05-10
NO20024742D0 (no) 2002-10-02
SK14132002A3 (sk) 2003-04-01
EE200200576A (et) 2004-06-15
WO2001077107A8 (en) 2003-02-13
US20040024035A1 (en) 2004-02-05
AU2001244726A1 (en) 2001-10-23
KR20020028865A (ko) 2002-04-17
HUP0300434A3 (en) 2004-11-29
HUP0300434A2 (hu) 2003-06-28
CN1444582A (zh) 2003-09-24
NO20024742L (no) 2002-11-25
WO2001077107B1 (en) 2001-12-20
EP1268473A1 (en) 2003-01-02
US6716863B2 (en) 2004-04-06
MXPA02009621A (es) 2003-05-14
CA2404760A1 (en) 2001-10-18
PE20011178A1 (es) 2001-11-19
PL365787A1 (en) 2005-01-10
IL152115A0 (en) 2003-05-29
US20020173526A1 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
CO5261589A1 (es) Compuestos heterociclicos, su produccion y su utilizacion
CO5150150A1 (es) 4-oxo-1,4-dihidro-3-quinoleincarboxamidas como agentes antivirales
CO5271657A1 (es) Derivados de azaindol
GB0226931D0 (en) Chemical compounds
CO5280198A1 (es) Inhibidores a base de pirrolidina fusionada con ciclopropilo de dipeptidil peptidasa iv y metodo
CO5140093A1 (es) Epotilonas c 21 modificadas
NO20016162D0 (no) 5-cyano-2-aminopyrimidinderivater
CO5930056A1 (es) Composiciones con ciclopopenos
DK1200426T3 (da) Substituerede thien-3-yl-sulfonylamino(thio)carbonyl-tiazolin(thi)oner
DE60112974D1 (en) Carbolinderivate
AR028706A1 (es) Tiazina oxazolidinona
ATE377001T1 (de) Pleuromutilinderivate als antimikrobielle mittel
ECSP045078A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplásicos
ATE346067T1 (de) Carbolinderivate
MXPA02012076A (es) Compuestos quimicos.
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
MXPA03002911A (es) Compuestos quimicos.
AR042706A1 (es) Compuestos (2-carboxamido)(3-amino) tiofenos y su uso para el tratamiento del cancer
MXPA02012659A (es) Derivados de pirazindiona condensados.
PE20020144A1 (es) Derivados de pleuromutilinas como agentes antibacterianos
ATE453389T1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
DE60112960D1 (de) Kondensierte pyridoindolderivate
BRPI0417007A (pt) agentes antivirais de diazaindol-dicarbonil-piperazinila
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
DK1305037T3 (da) Smertestillende medikament

Legal Events

Date Code Title Description
FA Application withdrawn